US00887A2042 - Common Stock
Includes initial funding of approximately $20 million, as well as the potential for additional proceeds of approximately $20 million from exercise of three-year warrants issued in offering
Includes initial funding of approximately $20 million, as well as the potential for additional proceeds of approximately $20 million from exercise of...
Low-dose LTI-03 (2.5 mg BID), a Caveolin-1 related peptide, reduced expression of multiple profibrotic proteins in both pathological basal-like cells and...
Aileron Therapeutics just reported results for the fourth quarter of 2023.
Topline results from Phase 1b study of LTI-03, a novel Caveolin-1-related peptide in development for the treatment of idiopathic pulmonary fibrosis,...
Topline results from Phase 1b study of LTI-03, Aileron’s novel Caveolin-1-related peptide in development for the treatment of idiopathic pulmonary fibrosis, expected in the second quarter of 2024
Topline results from Phase 1b study of LTI-03, Aileron’s novel Caveolin-1-related peptide in development for the treatment of idiopathic pulmonary...
Panel discussion will highlight LTI-03, Aileron’s novel Caveolin-1-related peptide, for the treatment of idiopathic pulmonary fibrosis
Panel discussion will highlight LTI-03, Aileron’s novel Caveolin-1-related peptide, for the treatment of idiopathic pulmonary fibrosis...
Aileron Therapeutics files prospectus for proposed resale of 7.06 million common shares by selling stockholders.
We're starting out the final day of trading this week with a breakdown of the biggest pre-market stock movers for Friday morning!
It's time to dive into the biggest pre-market stock movers for Friday morning as we check out the winners and losers today!
/PRNewswire/ -- Aileron Therapeutics, Inc. ("Aileron") (NASDAQ: ALRN) today announced it has acquired Lung Therapeutics, Inc. ("Lung Tx"), a privately held...
Aileron Therapeutics (ALRN) shed ~38% on Tuesday after the company disclosed plans to explore strategic alternatives, including a sale, and said that its Phase 1b study for...
BOSTON, Feb. 21, 2023 (GLOBE NEWSWIRE) -- Aileron Therapeutics (Nasdaq: ALRN) today announced that a review of initial data from its Phase 1b...